Home
Live Updates
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular ... : vimarsana.com
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular ...
Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease
Related Keywords
France ,
United Kingdom ,
Mexico ,
United States ,
Japan ,
Switzerland ,
Canada ,
Swiss ,
America ,
American ,
Patrickj Mcenany ,
David Schull Russo ,
Drug Administration ,
European Medicines Agency ,
Moelis Company ,
Investor Contact Mary Coleman Catalyst Pharmaceuticals Inc ,
Life Science Alliance ,
Chiesi Group ,
Japan Should Santhera Pursue Partnership Opportunities ,
Steering Committee ,
Health Canada ,
Catalyst Pharmaceuticals ,
Santhera Pharmaceuticals Holding ,
Catalyst Pharmaceuticals Inc ,
Santhera Pharmaceuticals ,
Development Rights For Vamorolone ,
Regulatory Agency ,
Currently Under Review ,
Duchenne Muscular Dystrophy ,
Rare Neuromuscular ,
Granted Fast Track ,
Orphan Drug Designation ,
Treat Duchenne Muscular ,
Launch Vamorolone ,
Regulatory Approval ,
Include Commercial ,
Future Development Rights ,
Additional Indications ,
North America ,
First Negotiation ,
Japan Should Santhera Pursue Partnership ,
Also Includes ,
Strategic Equity Investment ,
North American ,
New Drug Application ,
Prescription Drug User Fee Act ,
Orphan Drug ,
Fast Track ,
Rare Pediatric Disease ,
Joint Steering Committee ,
Promising Innovative Medicine ,
Proc Natl Acad Sci United States ,
United Kingdom Medicines ,
Full Prescribing ,
Safety Information ,
Full Prescribing Information ,
Annual Report ,
Quarterly Report ,
Contact David Schull Russo Partners ,
vimarsana.com © 2020. All Rights Reserved.